The DOI matches its Crossref record; 51 of the 52 references it cites were found in a registry or an index; 3 of the 66 sources its claims cite were checked for support.
ACTH Stimulation Test for the Diagnosis of Secondary Adrenal Insufficiency: Light and Shadow
Open accessAbstract
Secondary Adrenal Insufficiency (SAI) is a condition characterized by inappropriately low ACTH secretion due to a disease or injury to the hypothalamus or the pituitary. The evaluation when suspected is often challenging for the non-specific symptoms, the rarity of the disease, and the pitfalls associated with laboratory tests. A prompt and correct diagnosis of SAI is essential because although an adequate hormonal replacement therapy could be lifesaving, inappropriate life-long therapy with steroids can be harmful. The gold standard test for assessing the hypothalamus-pituitary-adrenal axis (HPA) is the insulin tolerance test (ITT), but due to safety issues is not widely used. Conversely, the ACTH stimulation test is a safer and well-tolerated tool for SAI diagnosis. However, data about its diagnostic accuracy show great variability due to both technical and interpretative aspects, such as dose, route of administration, the timing of the test, and assay used for cortisol measurements. Consequently, the clinical background of the patient and the pretest probability of HPA axis impairment become of paramount importance. We aimed to summarize the recent literature evidence in the conduction and interpretation of the ACTH stimulation test for the diagnosis of SAI to provide updated insights on its correct use in clinical practice.
Overview
CoChat Summary
TL;DR
This narrative review summarizes evidence on the ACTH stimulation test for secondary adrenal insufficiency (SAI), emphasizing that both standard- and low-dose tests are useful but accuracy varies with protocol, timing, and cortisol assay. It highlights assay-specific cortisol cutoffs and the need to select patients by pretest probability, while noting unresolved technical and validation issues.
Key findings
- The ACTH stimulation test is safer and better tolerated than the insulin tolerance test for SAI, but diagnostic accuracy varies by dose, route, timing, and assay; a patient-level meta-analysis found low-dose ACTH superior to standard-dose ACTH (AUC 0.94 vs. 0.85, p < 0.001).
- Low-dose preparation is technically problematic: surveyed dilution methods delivered actual doses from 0.16 to 0.81 μg instead of 1 μg, up to seven-fold less; the minimal ACTH dose reported to induce peak cortisol was 0.5 μg cosyntropin.
- Interpretation depends on assay: the traditional peak cortisol cutoff >18.1 μg/dL (500 nmol/L) excludes AI, but newer specific assays measure cortisol 20–36% lower; suggested 30-min cutoffs are 12.6–14.6 μg/dL with Elecsys Cortisol II and 13.3–14.9 μg/dL with Beckman Access.
- Guidelines suggest testing 6 weeks after pituitary surgery and ≥18 h after the last hydrocortisone dose, with morning cortisol 3–15 μg/dL as the grey zone for testing; adding a 60-min cortisol to 30-min sampling reclassifies 10–24% of patients from AI to sufficient.
Methods
- Narrative review using PubMed; search terms included “ACTH stimulation test,” “cosyntropin stimulation test,” or “short Synacthen Test (SST)” combined with “secondary adrenal insufficiency” or “secondary hypoadrenalism,” “pituitary surgery,” “pituitary disease,” or “trans-nasal-sphenoidal surgery.”
- The authors reviewed English-language papers on the ACTH stimulation test and selected those on adrenal insufficiency secondary to pituitary surgery or pituitary disease.
Limitations
- Stated: there is no consensus on the most reliable ACTH test protocol; low-dose dilution methods vary and often underdeliver corticotropin; studies proposing new assay-specific cutoffs mostly used standard-dose ACTH, small cohorts, and did not differentiate causes of AI; large prospective validation is needed.
- Stated: few studies address the appropriate frequency of repeat dynamic testing; data on glucagon and metyrapone tests are limited, with no comparative adult studies of glucagon vs. ACTH and limited pediatric data.
- Evident: as a narrative review, it does not report a systematic search, risk-of-bias assessment, or quantitative synthesis; conclusions therefore rest on heterogeneous studies and expert interpretation.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
3 Valid · 0 Not valid · 45 Not checked · 13 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In this study, an immunoassay using monoclonal antibodies was used to detect the cortisol levels, and the local laboratory established as a cutoff for the ACTH test failure a cortisol value ≤ 16.3 μg/dL (450 nmol/L) at 30 min after the injection of the corticotropin analog.”
§ ACTH Stimulation Test for the Diagnosis of Secondary Adrenal Insufficiency: Light and Shadow > 3. Patients to Be Tested and Timing for Testing
What the sources say
- Partly supportedcites [13] Ravindran, 2022, Pre-test Cortisol Levels in Predicting Short Synacthen Test Outcome: A Retrospective Analysis, Clin. Med. Insights Endocrinol. Diabetes sourceExperimental — accuracy not yet measured
The Methods (SST protocol and testing) state verbatim that 'The local laboratory established cut off for SST failure was a serum cortisol concentration of ⩽450 nmol/L at 30 minutes after injection of Synacthen', and Synacthen/tetracosactide is described in the Discussion as the corticotropin analogue used, so the cutoff (⩽450 nmol/L ≈ 16.3 μg/dL), the 30-minute sampling point and the injected agent are supported. However, the assay part of the sentence is not supported by our copy: the Methods (Cortisol Assay) only name 'the Architect Assay (Abbott Diagnostics, North Illinois, Chicago, USA)' and give its reference intervals, with no description of it as an immunoassay and no mention of monoclonal antibodies anywhere in the text (searched: monoclonal antibody, immunoassay, Architect assay methodology, 16.3 μg/dL). (LLM, conf=0.70)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“cortisol at baseline ≤ 4.49 μg/dL (124 nmol/L) predicts the failure to reach the peak at the test in 100% of the patients, while a cortisol ≥ 11.38 μg/dL (314 nmol/L) predicts a successful response.”
§ ACTH Stimulation Test for the Diagnosis of Secondary Adrenal Insufficiency: Light and Shadow > 3. Patients to Be Tested and Timing for Testing
What the sources say
- Partly supportedcites [13] Ravindran, 2022, Pre-test Cortisol Levels in Predicting Short Synacthen Test Outcome: A Retrospective Analysis, Clin. Med. Insights Endocrinol. Diabetes sourceExperimental — accuracy not yet measured
The Results section (Group 1, 8-10 am, n=165) states exactly these numbers: Cort0 ⩽124 nmol/L (≈4.49 µg/dL) predicted an abnormal response with 100% specificity and PPV = 1.00, and Cort0 ⩾314 nmol/L (≈11.38 µg/dL) predicted an adequate response with 100% sensitivity — so the '100%' figures and unit conversions are the paper's own. However, both cut-offs are explicitly restricted to morning (8-10 am) SSTs; for SSTs at other times (Group 2) the paper reports ⩽47 nmol/L and ⩾323 nmol/L instead, and the Discussion and Conclusions warn that the findings apply 'only to the population tested in this analysis and the assay we have used' and 'should not be extrapolated'. The citing sentence drops this time-of-day and population/assay qualifier and presents the rule as holding 'in 100% of the patients'; note also that the failure rule's 100% figure is specificity/PPV, with sensitivity only 24%, so a reading of 'predicts failure in 100% of patients' as capturing all failures would overstate it further. (LLM, conf=0.80)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Serum cortisol concentrations measured with the newer assays when compared to those measured with the older ones are sharply lower by 20 up to 36%, according to different studies and assays [45,46,47].”
§ ACTH Stimulation Test for the Diagnosis of Secondary Adrenal Insufficiency: Light and Shadow > 6. How to Interpret the Results: Old and New Cortisol Cutoffs
What the sources say
- Not checked — no full text of the sourcecites [45] Ueland, 2018, The Short Cosyntropin Test Revisited: New Normal Reference Range Using LC-MS/MS, J. Clin. Endocrinol. Metab. source
- Not checked — no full text of the sourcecites [46] Pickett, 2013, Method-specific serum cortisol responses to the adrenocorticotrophin test: Comparison of gas chromatography-mass spectrometry and five automated immunoassays, Clin. Endocrinol. source
- Partly supportedcites [47] Grassi, 2020, Minding the gap between cortisol levels measured with second-generation assays and current diagnostic thresholds for the diagnosis of adrenal insufficiency: A single-center experience, Hormones sourceExperimental — accuracy not yet measured
Our copy of Grassi et al. (2020) supports the direction and the upper end of the range: the Discussion states that 'the mean R2 cortisol concentrations were about 36% lower than those of R1 at all time points', and the Results (Bland-Altman) report R1 values ~36% higher than R2 (from 12.7 to 58.7%) and ~32% higher than LC-MS/MS; the Abstract Conclusion generalises that 'the use of more specific cortisol assays results in lower cortisol concentrations'. However, this is a single-centre study of 30 adults undergoing ACTH stimulation with two Roche assays (R1 vs R2) — it does not report a 20% lower bound, nor a range spanning 'different studies and assays', so that part of the claim is not attributable to this source (it rests on the companion citations 45/46/47). (LLM, conf=0.75)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“the latter test has more false positives due to supra-physiological adrenal stimulation [18].”
§ ACTH Stimulation Test for the Diagnosis of Secondary Adrenal Insufficiency: Light and Shadow > 4. How to Perform the Test
What the sources say
- Not checked — no full text of the sourcecites [18] Ospina, 2016, ACTH Stimulation Tests for the Diagnosis of Adrenal Insufficiency: Systematic Review and Meta-Analysis, J. Clin. Endocrinol. Metab. source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A statement the paper makes itself — it cites no source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“However, data about its diagnostic accuracy show great variability due to both technical and interpretative aspects, such as dose, route of administration, the timing of the test, and assay used for cortisol measurements.”
§ ACTH Stimulation Test for the Diagnosis of Secondary Adrenal Insufficiency: Light and Shadow > Abstract
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
26 more claims
Create a free account to see all 61 claims and to verify the 56 references still open.
- It may state two separate claims as one. 26
- Probably not a substantial claim. 9
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ ACTH Stimulation Test for the Diagnosis of Secondary Adrenal Insufficiency: Light and Shadow > 7. When to Repeat the Test?
“Pofi et al. demonstrated that HPA axis recovery can occur as late as 9 to 12 months after TNS demonstrating the need for periodic reassessment of patients who initially failed to respond to the ACTH test [30].”
§ ACTH Stimulation Test for the Diagnosis of Secondary Adrenal Insufficiency: Light and Shadow > References
“30. Munro V. Elnenaei M. Doucette S. Clarke D.B. Imran S.A. The effect of time of day testing and utility of 30 and 60 minute cortisol values in the 250 mcg ACTH stimulation test”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ ACTH Stimulation Test for the Diagnosis of Secondary Adrenal Insufficiency: Light and Shadow > 7. When to Repeat the Test?
“The same group found that a 30-min cortisol level above or below 12.7 μg /dL (350 nmol/L) across the first ACTH Test after TNS best predicts HPA axis recovery, enabling early identification of subgroups more likely to recover and hence patients to be prioritized for retesting [31].”
§ ACTH Stimulation Test for the Diagnosis of Secondary Adrenal Insufficiency: Light and Shadow > References
“31. Cartaya J. Misra M. The low-dose ACTH stimulation test: Is 30 minutes long enough?”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ ACTH Stimulation Test for the Diagnosis of Secondary Adrenal Insufficiency: Light and Shadow > 4. How to Perform the Test
“ranging from 0.16 μg to 0.81 μg”
§ ACTH Stimulation Test for the Diagnosis of Secondary Adrenal Insufficiency: Light and Shadow > 4. How to Perform the Test
“The first one was also the most accurate method with a final real delivered dose close to the desired 1 μg (0.79 to 0.84 μg)”
Citations
Cites
Bornstein, S. R., Allolio, B., Arlt, W., Barthel, A., Don-Wauchope, A., Hammer, G. D., Husebye, E. S., Merke, D. P., Murad, M. H., Stratakis, C. A., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1710 · Cited by 1,769 · cited 3×
“The diagnosis of PAI is usually overt and is based on clinical signs and symptoms (often the ones of an adrenal crisis), possibly combined with skin hyperpigmentation, very low serum cortisol in the morning, and high ACTH [5] and since confirmatory stimulation tests are not always required, most centers do not routine…”
BackgroundMethodHormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline
Fleseriu, M., Hashim, I. A., Karavitaki, N., Melmed, S., Murad, M. H., Salvatori, R., & Samuels, M. H. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2118 · Cited by 945 · cited 2×
“1 μg/dL (500 nmol/L) at 30 or 60 min after corticotropin analogs administration indicates an appropriate cortisol secretion and therefore excludes the diagnosis of AI [5,11].”
BackgroundMethodArlt, W., & Allolio, B. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13492-7 · Cited by 819
Clinical review 62: Laboratory assessment of adrenal insufficiency.
Grinspoon, S. K., & Biller, B. M. (1994) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.79.4.7962298 · Cited by 442
Corticotropin tests for hypothalamic-pituitary- adrenal insufficiency: a metaanalysis
Kazlauskaite, R., Evans, A. T., Villabona, C. V., Abdu, T. A. M., Ambrosi, B., Atkinson, A. B., Choi, C. H., Clayton, R. N., Courtney, C. H., Gonc, E. N., et al. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0710 · Cited by 385 · cited 1×
“corticotropin analog, in clinical practice the cortisol is mostly measured only at baseline and 30 min after the ACTH injection [19].”
Husebye, E. S., Pearce, S. H., Krone, N. P., & Kämpe, O. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00136-7 · Cited by 378
Diagnosis of Adrenal Insufficiency
Dorin, R. I., Qualls, C. R., & Crapo, L. M. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-139-3-200308050-00009 · Cited by 374 · cited 1×
“Despite it is still a matter of debate, it seems that the low dose provides the same or even superior diagnostic accuracy compared to the standard one in the evaluation of SAI [9,17,18].”
ResultOspina, N. S., Al Nofal, A., Bancos, I., Javed, A., Benkhadra, K., Kapoor, E., Lteif, A. N., Natt, N., & Murad, M. H. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1700 · Cited by 247
Endoscopic endonasal approach for pituitary adenomas: A series of 555 patients
Paluzzi, A., Fernandez-Miranda, J. C., Tonya Stefko, S., Challinor, S., Snyderman, C. H., & Gardner, P. A. (2014) · Pituitary · doi:10.1007/s11102-013-0502-4 · Cited by 185
Javorsky, B. R., Raff, H., Carroll, T. B., Algeciras-Schimnich, A., Singh, R. J., Colón-Franco, J. M., & Findling, J. W. (2021) · Journal of the Endocrine Society · doi:10.1210/jendso/bvab022 · Cited by 171
Cited by
Sofer, Y., Osher, E., Ahmad, W. A., Greenman, Y., Moshe, Y., Shaklai, S., Yaron, M., Serebro, M., Tordjman, K. M., & Stern, N. (2025) · Obesity Facts · doi:10.1159/000543449 · Cited by 7
Valea, A., Nistor, C., Ciobica, M.-L., Sima, O.-C., & Carşote, M. (2024) · Diagnostics · doi:10.3390/diagnostics14121303 · Cited by 6
Increased adrenocortical activity in patients with vasovagal syncope
Bačkorová, B., Lazúrová, Z., Lewaśkiewicz, P., Mitro, P., & Lazúrová, I. (2024) · Autonomic Neuroscience · doi:10.1016/j.autneu.2024.103196 · Cited by 5
Atila, C., Camerin, S.-J., Liechti, M. E., & Christ‐Crain, M. (2025) · Endocrine Connections · doi:10.1530/ec-25-0254 · Cited by 4
Impact of systemic treatments for advanced thyroid cancer on the adrenal cortex
Colombo, C., Ceruti, D., Succi, M., Leo, S. D., Trevisan, M., Moneta, C., & Fugazzola, L. (2022) · European Thyroid Journal · doi:10.1530/etj-23-0246 · Cited by 3
Metadata
- Authors
- Birtolo, M. F., Antonini, S., Saladino, A., Zampetti, B., Lavezzi, E., Chiodini, I., Mazziotti, G., Lania, A. G. A., & Cozzi, R.
- Affiliations
- Humanitas University (IT)
- Fondazione IRCCS Istituto Neurologico Carlo Besta (IT)
- Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda (IT)
- University of Milan (IT)
- Corresponding author
- Lania, Andrea G. A.
- ORCID
- Venue
- Biomedicines
- Publisher
- MDPI AG
- Published
- 2023-03-15
- Volume
- 11
- Issue
- 3
- Pages
- 904
- ISSN
- 2227-9059 (ISSN-L)
- PMC
- PMC10045406
- OpenAlex
- W4324357303
- Semantic Scholar
- 6a2ba4205ef07392dfe50eb1ca1b4d54c29672bc
- Cited by
- 19
- References
- 52
- Citations by year
- 2026: 4 · 2025: 8 · 2024: 4 · 2023: 2
- FWCI
- 0.53
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Biomedicines (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Life Sciences › Neuroscience › Behavioral Neuroscience › Stress Responses and Cortisol
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
- Keywords
- secondary adrenal insufficiency, ACTH stimulation test, hypothalamic-pituitary-adrenal axis, insulin tolerance test, cortisol measurement, diagnostic accuracy, test interpretation, steroid replacement therapy, pituitary disorders, hypothalamic disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-11-14, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-11-14 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: ACTH Stimulation Test for the Diagnosis of Secondary Adrenal Insufficiency: Light and Shadow. https://app.cochat.ai/papers/10.3390/biomedicines11030904
- The paper
- Birtolo, M. F., Antonini, S., Saladino, A., Zampetti, B., Lavezzi, E., Chiodini, I., Mazziotti, G., Lania, A. G. A., & Cozzi, R. (2023). ACTH Stimulation Test for the Diagnosis of Secondary Adrenal Insufficiency: Light and Shadow. Biomedicines. https://doi.org/10.3390/biomedicines11030904
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
